Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 86.73M P/E - EPS this Y 62.80% Ern Qtrly Grth -
Income -106.81M Forward P/E -8.35 EPS next Y -19.00% 50D Avg Chg 9.00%
Sales 14.02M PEG - EPS past 5Y - 200D Avg Chg 39.00%
Dividend N/A Price/Book 6.24 EPS next 5Y - 52W High Chg -23.00%
Recommedations 1.20 Quick Ratio 6.53 Shares Outstanding 59.69M 52W Low Chg 223.00%
Insider Own 18.10% ROA -20.81% Shares Float 44.03M Beta 1.66
Inst Own 37.51% ROE -156.45% Shares Shorted/Prior 3.24M/2.65M Price 7.10
Gross Margin -63.54% Profit Margin - Avg. Volume 259,943 Target Price 35.33
Oper. Margin -362.02% Earnings Date May 3 Volume 70,175 Change -2.07%
About Immunome, Inc.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome, Inc. News
04/05/24 Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
04/04/24 New Strong Sell Stocks for April 4th
03/28/24 Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
03/26/24 Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
03/26/24 Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
03/22/24 Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
03/07/24 Immunome to Participate in the Leerink Partners Global Biopharma Conference
03/01/24 Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
02/20/24 Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
02/20/24 Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
02/16/24 Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
02/13/24 Immunome Announces Pricing of Public Offering of Common Stock
02/13/24 Immunome Announces Proposed Public Offering of Common Stock
02/10/24 Insiders See US$1.25m Investment In Immunome Jump Last Week
02/07/24 Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
02/06/24 Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
02/05/24 Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/08/24 Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
01/04/24 Immunome Appoints Phil Roberts as Chief Technical Officer
01/03/24 Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
IMNM Chatroom

User Image Jeff9905 Posted - 12 hours ago

$IMNM 2 more job postings yesterday

User Image HunterT Posted - 2 days ago

$IMNM oof cmon

User Image ViractaTrader77 Posted - 4 days ago

$VINC $IMNM Key in ADC Space is to own a basket. https://twitter.com/BiotechTVHQ/status/1775900116924448891/mediaViewer?currentTweet=1775900116924448891&currentTweetUser=BiotechTVHQ $BOLT $CTMX

User Image Elliotwavedave Posted - 1 week ago

$IMNM sit tight we have been in a bear market the last 30 days.

User Image HunterT Posted - 1 week ago

$IMNM Bidenomics “it’s working”

User Image Jeff9905 Posted - 1 week ago

$IMNM guess all those who were suckered into the secondary are going down with the rest of us.

User Image Stock_Titan Posted - 1 week ago

$IMNM Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting https://www.stocktitan.net/news/IMNM/immunome-to-present-preclinical-data-for-im-3050-its-lead-cbopg3x5jlv8.html

User Image Fast_Eddie_Felson Posted - 1 week ago

$IMNM so this was pumped to 30 and lost 1/3 of its value. Looks like a pump and dump for most part (again).

User Image HunterT Posted - 1 week ago

$IMNM wow

User Image Elliotwavedave Posted - 1 week ago

$IMNM bots disappeared. Good riddens!

User Image frontiere Posted - 1 week ago

Active patience is also holding $IMNM for 2 years as they keep making wise decisions and stock appreciates from ~$2s to highs of $30 — and not selling! (Again, not my trade)

User Image DonCorleone77 Posted - 2 weeks ago

$IMNM Immunome files to sell 2.23M shares of common stock for holders

User Image HunterT Posted - 2 weeks ago

$IMNM ewww 🙄

User Image Biotech_Beast Posted - 2 weeks ago

$IMNM I take another look at Immunome following the rally in the antibody-drug conjugate space. https://seekingalpha.com/article/4681782-immunome-an-oncology-powerhouse-in-the-making

User Image ViractaTrader77 Posted - 2 weeks ago

$STRO worth at least $1 billion market cap. $MRK bought a Ror-1 for $2.8 billion. Sutro has one of these. $IMNM so does Immunome and their market cap triple sutro’s.

User Image ViractaTrader77 Posted - 2 weeks ago

Trading at cash with $IMGN and $IMNM type ADC’s. Easy double in Sutro Biopharma from here. $STRO

User Image Stock_Titan Posted - 03/28/24

$IMNM Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets https://www.stocktitan.net/news/IMNM/immunome-reports-full-year-2023-financial-results-and-provides-t90avsiu5vie.html

User Image HunterT Posted - 03/28/24

@Zydecoshuffle sorry wrong ticker $IMNM 👈🏻

User Image ViractaTrader77 Posted - 03/28/24

$STRO has no enterprise value. Could triple from here. Has Ror-1 like $IMNM and they are at $1.5 billion market cap. And seeking alpha says there drug is better than $IMGN

User Image lecorb Posted - 03/28/24

$IMNM Imunon GAAP EPS of -$2.16 beats by $0.07 Mar. 28, 2024 8:05 AM ETImunon, Inc. (IMNN) StockBy: Gaurav Batavia, SA News Editor Imunon press release (NASDAQ:IMNN): FY GAAP EPS of -$2.16 beats by $0.07. The Company ended 2023 with $15.7 million in cash, investments and accrued interest receivable. Along with future planned sales of the Company’s remaining $1.3 million of New Jersey NOLs, the Company believes it has sufficient capital resources to fund its operations into the fourth quarter of 2024. https://seekingalpha.com/news/4084832-imunon-gaap-eps-of-2_16-beats-0_07?mailingid=34846497&messageid=2900&serial=34846497.671&utm_campaign=rta-stock-news&utm_content=link-3&utm_medium=email&utm_source=seeking_alpha&utm_term=34846497.671

User Image AnomalyDetective Posted - 03/27/24

$IMNM (Week 13 MDA) first of the Week 13 picks to break 10% gains in a short trading week for members with all new Week 14 MDA picks out tomorrow. $LABU and prior #Biotechs in very strong breakout conditions. www.vmbreakouts.com

User Image NotHopeJustFacts Posted - 03/27/24

$ADXS $ADXSD someone in here does know (honest question) if shareholders get a % of the stock AYALA got from $IMNM , and the 20M is for development ? so basically management got richer at the expense of common shareholders ?

User Image Elliotwavedave Posted - 03/26/24

$IMNM get in while it’s still cheap boys and girls

User Image Stock_Titan Posted - 03/26/24

$IMNM Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala https://www.stocktitan.net/news/IMNM/immunome-completes-acquisition-of-al102-a-phase-3-asset-for-the-2cxy0sl4c3c3.html

User Image HunterT Posted - 03/25/24

$IMNM what morons are selling over $25🤨

User Image Jeff9905 Posted - 03/24/24

$IMNM 3 more job openings. Plot getting thicker by the week!

User Image ViractaTrader77 Posted - 03/23/24

$ADCT 40% cr in 2nd line aml at MBRX with $12 mil market cap at 1/2 cash. 2 mil shs float. $IMNM $VKTX

User Image HunterT Posted - 03/22/24

$IMNM come on girl! Gitty up!

User Image Jjpratt19 Posted - 03/20/24

$IMNM maybe now that we've had the Fed meeting and this year's outlook hasn't changed yet, we finally get some relief after the past couple weeks. I have a feeling that most bio was being held down a little with fear that the hot inflation data may cause a change in tune for the possible rate cuts this year.

User Image FlynancialAnalyst Posted - 03/19/24

link share feature is lowkey one of fav features of new TrendEdge.app v 4.0.x Completely seamless, so we all see the same results $VKTX $MRUS $IMNM $FULC $SMMT

Analyst Ratings
Guggenheim Buy Apr 15, 24
Wedbush Outperform Apr 1, 24
Wedbush Outperform Jan 23, 24
Wedbush Outperform Dec 19, 23
Cantor Fitzgerald Overweight Mar 20, 23
Chardan Capital Buy Mar 17, 23
Cantor Fitzgerald Overweight Oct 29, 21
Chardan Capital Buy Oct 27, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SIEGALL CLAY B President and CEO President and CEO Oct 02 Buy 5.91 169,204 999,996 319,636 10/04/23
Turner Bruce Chief Strategy Offic.. Chief Strategy Officer Oct 02 Buy 5.91 42,300 249,993 42,300 10/04/23
RAPP MICHAEL Director Director Sep 13 Buy 17.92 45,950 823,424 182,780 09/13/21